Scinai Immunotherapeutics
SCNI
14 hedge funds and large institutions have $2.58M invested in Scinai Immunotherapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
27% more funds holding
Funds holding: 11 → 14 (+3)
0.11% less ownership
Funds ownership: 2.69% → 2.58% (-0.11%)
20% less capital inflows, than outflows
Capital inflows: $275K | Capital outflows: $345K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank Hapoalim BM
Tel Aviv,
Israel
|
+$168K |
| 2 |
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$68.6K |
| 3 |
DAFNA Capital Management
Los Angeles,
California
|
+$18.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.5K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$168K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$162K |
| 3 |
Morgan Stanley
New York
|
-$12.5K |
| 4 |
Calton & Associates
Tampa,
Florida
|
-$1K |
| 5 |
Edge Wealth Management
New York
|
-$1K |
SCNI Hedge Fund Activity: Q1 2018 in Review
14 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2018, worth a combined $2.58M — down 0.92% from $2.61M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SCNI positions and 2 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Bank Hapoalim BM, opening a new position worth an estimated $168K. The largest seller was Renaissance Technologies, cutting an estimated $168K.
- 14 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2018, up from 11 in Q4 2017.
- Funds reported $2.58M of Scinai Immunotherapeutics stock for Q1 2018, down 0.92% quarter-over-quarter.
- 5 funds opened new Scinai Immunotherapeutics positions in Q1 2018 and 2 closed out, a net change of +3 holders.
- The largest Scinai Immunotherapeutics buyer in Q1 2018 was Bank Hapoalim BM, an estimated $168K added.
- The largest Scinai Immunotherapeutics seller in Q1 2018 was Renaissance Technologies, an estimated $168K sold.
Based on aggregated 13F filings for Q1 2018.